Abstract: Isolated peptides capable of reducing the amount of dexamethasone-induced spleen and/or thymus weight loss in a mouse are disclosed as well as uses thereof.

Abstract: The present invention relates to uses of a peptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, analogues and derivatives thereof, for the treatment of neurodegenerative diseases, such as amyotrophic lateral sclerosis (ALS). The present invention further provides a method for assessing responsiveness to treatment with the peptide of the invention. In addition, the present invention relates to prognosis of ALS progression, using Akt and phosphorylated Akt as biomarkers.

Abstract: Isolated peptides capable of reducing the amount of dexamethasone-induced spleen and/or thymus weight loss in a mouse are disclosed. Uses thereof for treating inflammatory or degenerative diseases are also disclosed.

Abstract: Isolated peptides capable of reducing the amount of dexamethasone-induced spleen and/or thymus weight loss in a mouse are disclosed as well as uses thereof.

Abstract: Compositions and methods of using same for treating Amyotrophic Lateral Sclerosis (ALS) are provided. Accordingly there is provided a method of treating ALS in a human subject in need thereof, the method comprising intravenously (IV) administering to the subject 2-5 mg/kg of a peptide comprising an amino acid sequence as set forth in SEQ ID NO: 1. Also provided are compositions and unit dosage forms comprising a peptide comprising an amino acid sequence as set forth in SEQ ID NO: 1.

Abstract: The present invention relates to uses of a peptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, analogues and derivatives thereof, for the treatment of neurodegenerative diseases, such as amyotrophic lateral sclerosis (ALS). The present invention further provides a method for assessing responsiveness to treatment with the peptide of the invention. In addition, the present invention relates to prognosis of ALS progression, using Akt and phosphorylated Akt as biomarkers.

Abstract: A system, method and devices for text input system for disambiguating keystrokes entered by a user, comprising a plurality of data keys, said plurality of data keys configured to facilitate the smallest number of required language letters, and to facilitate between two to six characters per each data key, by a further smaller number of keys, including touch-based key strokes facilitating by a differential way both precise single character selection and the selection of all letters facilitated by this key, including integrated word prediction function; each of said plurality of data keys configured to facilitate at least one but no more than three characters on each side of the symmetry axis of the key, such symmetry axis can be vertical or horizontal; and are adapted for enabling entry of an at least one word by a succession of touch-based keystrokes and a word prediction function on said keyboard.

Abstract: The present invention relates to uses of a peptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, analogues and derivatives thereof, for the treatment of neurodegenerative diseases, such as amyotrophic lateral sclerosis (ALS). The present invention further provides a method for assessing responsiveness to treatment with the peptide of the invention. In addition, the present invention relates to prognosis of ALS progression, using Akt and phosphorylated Akt as biomarkers.

Abstract: The present invention relates to uses of a peptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, analogs and derivatives thereof, for the treatment of neurodegenerative diseases, such as amyotrophic lateral sclerosis (ALS). The present invention further provides a method for assessing responsiveness to treatment with the peptide of the invention. In addition, the present invention relates to prognosis of ALS progression, using Akt and phosphorylated Akt as biomarkers.

Abstract: A system, method and devices for text input system for disambiguating keystrokes entered by a user, comprising a plurality of data keys, said plurality of data keys configured to facilitate the smallest number of required language letters, and to facilitate between two to six characters per each data key, by a further smaller number of keys, including touch-based key strokes facilitating by a differential way both precise single character selection and the selection of all letters facilitated by this key, including integrated word prediction function; each of said plurality of data keys configured to facilitate at least one but no more than three characters on each side of the symmetry axis of the key, such symmetry axis can be vertical or horizontal; and are adapted for enabling entry of an at least one word by a succession of touch-based keystrokes and a word prediction function on said keyboard.

Abstract: The present invention relates to uses of a peptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, analogues and derivatives thereof, for the treatment of neurodegenerative diseases, such as amyotrophic lateral sclerosis (ALS). The present invention further provides a method for assessing responsiveness to treatment with the peptide of the invention. In addition, the present invention relates to prognosis of ALS progression, using Akt and phosphorylated Akt as biomarkers.

Abstract: An apparatus including a first circuit and a second circuit. The first circuit may be configured to receive a first 2N-bit complex number and a second 2N-bit complex number, each having a first format, and to reformat the first and the second 2N-bit complex numbers to a second format such that a lower portion of each real and imaginary part of each 2N-bit complex number is positive. The second circuit may be configured to multiply the first and the second 2N-bit complex numbers using at least one N-bit signed complex multiplier, where N is an integer.

Abstract: The present invention relates to uses of a peptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, analogues and derivatives thereof, for the treatment of neurodegenerative diseases, such as amyotrophic lateral sclerosis (ALS). The present invention further provides a method for assessing responsiveness to treatment with the peptide of the invention. In addition, the present invention relates to prognosis of ALS progression, using Akt and phosphorylated Akt as biomarkers.

Abstract: An apparatus including a first circuit and a second circuit. The first circuit may be configured to receive a first 2N-bit complex number and a second 2N-bit complex number, each having a first format, and to reformat the first and the second 2N-bit complex numbers to a second format such that a lower portion of each real and imaginary part of each 2N-bit complex number is positive. The second circuit may be configured to multiply the first and the second 2N-bit complex numbers using at least one N-bit signed complex multiplier, where N is an integer.

Abstract: A character input system for a limited keyboard, in which a number of input keys in the keyboard is smaller than a number of characters in an input alphabet, the system comprising: a memory comprising a plurality of different mappings of said characters onto combinations of said keys; and a selector for allowing a user to select one of said mappings for character input. The different mappings are optimized for different users and different purposes, so that the user may select a mapping for simplicity of use, or one optimized for touch-typing, or for minimal key pressing or for minimal ambiguity or for other factors and combinations thereof.